Cargando…

1236. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States

BACKGROUND: A 20-valent pneumococcal conjugate vaccine (PCV20) is being developed to extend protection against pneumococcal disease beyond that of the 13-valent pneumococcal vaccine (PCV13). This is the first safety and immunogenicity study of PCV20 in healthy infants. METHODS: This randomized, doub...

Descripción completa

Detalles Bibliográficos
Autores principales:	Senders, Shelly, Klein, Nicola P, Lamberth, Erik, Thompson, Allison, Drozd, Jelena, Trammel, James, Peng, Yahong, Giardina, Peter, Jansen, Kathrin U, Gruber, William C, Scott, Daniel, Watson, Wendy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777493/ http://dx.doi.org/10.1093/ofid/ofaa439.1421

Ejemplares similares

Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2021)

1944. Tolerability and Safety of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Infants and Older Children in Global Studies
por: Flint, Laurence, et al.
Publicado: (2023)

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
por: Hurley, Donald, et al.
Publicado: (2020)

1728. Immune Responses to Cross-Reactive Serotypes 6C and 15C After 20-Valent Pneumococcal Conjugate Vaccine in Infants
por: Tamimi, Noor, et al.
Publicado: (2023)

3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older
por: Essink, Brandon, et al.
Publicado: (2020)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
por: Sabharwal, Charu, et al.
Publicado: (2022)

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years
por: Essink, Brandon, et al.
Publicado: (2021)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

20. Cost-Effectiveness of Implementing 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) for Adults Aged ≥19 Years with Underlying Conditions
por: Kobayashi, Miwako, et al.
Publicado: (2020)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
por: Gourzoulidis, George, et al.
Publicado: (2023)

1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age
por: Hurley, Donald, et al.
Publicado: (2020)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Perdrizet, Johnna, et al.
Publicado: (2021)

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Dhere, Rajeev, et al.
Publicado: (2022)

1104 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Immunogenicity in the Community Acquired Pneumonia Immunization Trial In Adults (CAPiTA)
por: Van Deursen, Anna M.M., et al.
Publicado: (2014)

Invasive pneumococcal surveillance to assess the potential benefits of extended spectrum conjugate vaccines (PCV15/PCV20) in older adults
por: Humphreys, Hilary, et al.
Publicado: (2023)

Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
por: Polistena, Barbara, et al.
Publicado: (2022)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

P68 - Immunogenicity of 13-valent conjugate pneumococcal vaccine (PCV13) in children with asthma or recurrent wheeze receiving inhaled corticosteroids (ICS)
por: Giannopoulou, Lefki, et al.
Publicado: (2014)

Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study
por: Bahuaud, Mathilde, et al.
Publicado: (2017)

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
por: Dirmesropian, S, et al.
Publicado: (2015)

1441. Doses of 13-Valent Conjugated Pneumococcal Vaccine (PCV13) for Patients With Multiple Myeloma (MM)
por: Sun, Hsin-Yun, et al.
Publicado: (2018)

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
por: Cordonnier, Catherine, et al.
Publicado: (2015)

Population genomics of pneumococcal carriage in South Africa following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) immunization
por: Javaid, Nida, et al.
Publicado: (2022)

1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations
por: Juergens, Christine, et al.
Publicado: (2018)

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
por: Kobayashi, Miwako, et al.
Publicado: (2022)

Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old
por: Fitz-Patrick, David, et al.
Publicado: (2023)

Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Gomez, Jorge A., et al.
Publicado: (2022)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
por: Warren, Sophie, et al.
Publicado: (2023)

Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico
por: Wasserman, Matt, et al.
Publicado: (2017)

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
por: Atwood, Mark, et al.
Publicado: (2018)

1337. Development, Maintenance, and Application of Opsonophagocytic Assays to Measure Functional Antibody Responses to Support a 20 Valent Pneumococcal Conjugate Vaccine
por: Scully, Ingrid L, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cvcuidhnfsli64areeelhthln1